Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer

NEXT STORY
Predictive Oncology CEO Discusses Corporate Milestones, Unique Approach to Cancer Research in Exclusive Broadcast
PREV STORY
Helius Medical Technologies, Inc. Announces Addition of P3 Health As New Authorized PoNS Treatment™ Clinic in Toronto, Canada
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Exagen enters second-year agreement with GSK to drive greater awareness about challenges facing lupus diagnosis and management

Albuquerque, NM and San Diego, CA, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Exagen, a ...

author_avatar
NASDAQ Market News

Results from Vericel’s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet

CAMBRIDGE, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer ...

author_avatar
NASDAQ Market News

BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer

author_avatar
NASDAQ Market News